Chapter 1: Discusses the evolution of hyperglycemia to type 2 diabetes mellitus, and glucose monitoring technology along with the new concept of “time in range”.

Chapter 2: Discusses the detailed molecular biology of insulin resistance and various patho-physiological mechanisms along with a detailed overview of all the available glucose-lowering therapies.

Chapters 3 and 5: Discuss various statin trials highlighting the huge unmet need of cardiovascular protection despite optimal statin use, additional role of biomarkers to help improve cardiovascular risk stratification, etiology, guidelines, recommendations, and ideal approach to managing patients with hypertension, asymptomatic coronary artery disease, heart failure, and stroke.

Chapter 4: Discusses elegantly the various causes of hyperglycemia in a young patient and clinical approach.

Chapter 6: Discusses the evolution of blood pressure control to reduce renal and cardiovascular outcomes.

Chapter 7: Discusses how diabetes and its therapeutics may be associated with various cancer and optimal strategies that might help reduce the incidence of cancer in diabetes.

Chapter 8: Provides an in-depth understanding and therapeutic approach of rheumatic conditions associated with type 2 diabetes mellitus. It also discusses the detailed use and side effects of steroids.

Chapter 9: Provides a detailed look into various immune dysregulatory pathways and types of infections a diabetic is at risk of with a highlight on COVID-19.

Chapter 10: It discusses the history and evolution of sugar consumption by Indians.

Chapter 11: Discusses management of glycemia in special situations.

Chapter 12: Provides an elegant overview of risk factor control.